Feds Further Link Avandia to Heart Risk

FDA, Senate reports lambaste GlaxoSmithKline, want to yank drug
By Polly Davis Doig,  Newser Staff
Posted Feb 20, 2010 7:09 AM CST
Feds Further Link Avandia to Heart Risk
Sen. Charles Grassley, R-Iowa, speaks in this 2006 file photo in Des Moines, Iowa. The government's evaluation of the diabetes pill Avandia confirms the heart risks reported in a study earlier this week, Grassley said.   (AP Photo/Matthew Putney, File)

(Newser) – Some 800 people every month suffer heart attacks or heart failure because of the diabetes medication Avandia, according to government reports obtained by the New York Times. Under fire since 2007, the GlaxoSmithKline drug was linked to 304 deaths in the final quarter of last year and hundreds of thousands still take it. Avandia “should be removed from the market," concludes one FDA study unequivocally.

story continues below

Not only does Avandia pose a significant cardiovascular risk, according to the reports, but a competing drug exists that is equally effective without the dangers. A bipartisan Senate committee report expected Monday also lambastes the drugmaker for not warning patients of the risk earlier. Committee co-chair Max Baucus says, "Patients trust drug companies with their health and their lives, and GlaxoSmithKline abused that trust." (Read more Avandia stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.